Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Myokardia Inc    MYOK

MYOKARDIA INC (MYOK)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/10/2018 07/11/2018 07/12/2018 07/13/2018 07/16/2018 Date
54.35(c) 54.25(c) 54.9(c) 55.65(c) 55.75(c) Last
422 769 356 483 152 680 190 839 237 701 Volume
+2.74% -0.18% +1.20% +1.37% +0.18% Change
More quotes
Financials (USD)
Sales 2018 26,4 M
EBIT 2018 -83,2 M
Net income 2018 -77,0 M
Finance 2018 324 M
Yield 2018 -
Sales 2019 15,7 M
EBIT 2019 -128 M
Net income 2019 -130 M
Finance 2019 240 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 71,4x
EV / Sales2019 126x
Capitalization 2 208 M
More Financials
Company
MyoKardia, Inc. operates as a biopharmaceutical company.It engages in the discovery, development, and commercialization of targeted therapies for the treatment of cardiovascular diseases.The firm focuses on the treatment of heritable cardiomyopathies, genetically-driven forms of heart failure that... 
More about the company
Surperformance© ratings of Myokardia Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on MYOKARDIA INC
07/03TODAY'S RESEARCH REPORTS ON TRENDING : Intercept Pharmaceuticals and MyoKardia
AC
06/29MYOKARDIA : Doses First Patient in Pivotal Phase 3 EXPLORER-HCM Trial of Mavacam..
AQ
06/27MYOKARDIA : Doses First Patient in Pivotal Phase 3 EXPLORER-HCM Trial of Mavacam..
AQ
06/26MYOKARDIA : Doses First Patient in Pivotal Phase 3 EXPLORER-HCM Trial of Mavacam..
AQ
06/15MYOKARDIA INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/24MYOKARDIA : Announces Pricing of Public Offering of Common Stock
AQ
05/23MYOKARDIA INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/23MYOKARDIA : Announces Pricing of Public Offering of Common Stock
AQ
05/22MYOKARDIA : Announces Proposed Public Offering of Common Stock
AQ
05/21MyoKardia Announces Proposed Public Offering of Common Stock
GL
More news
Sector news : Bio Therapeutic Drugs
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
07/16-$0.50 EPS Expected for Myokardia Inc $MYOK This Quarter  
07/15Myokardia $MYOK Earns Buy Rating from Analysts at Bank of America  
07/15-$0.50 EPS Expected for Myokardia Inc $MYOK This Quarter  
07/11Myokardia $MYOK Upgraded to “Hold” by Zacks Investment Research  
07/10Myokardia $MYOK Research Coverage Started at Bank of America  
More tweets
Qtime:203
News from SeekingAlpha
07/10Premarket analyst action - healthcare 
06/26MyoKardia doses first patient in Mavacamten Phase 3 trial of oHCM 
06/11Three Biotechs With Upcoming Data At Conferences 
05/31YOUR DAILY PHARMA SCOOP : Recent IPO And Offerings Review 
05/23MyoKardia prices common stock offering 
Chart MYOKARDIA INC
Duration : Period :
Myokardia Inc Technical Analysis Chart | MYOK | US62857M1053 | 4-Traders
Technical analysis trends MYOKARDIA INC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 71,3 $
Spread / Average Target 28%
EPS Revisions
Managers
NameTitle
Anastasios E. Gianakakos President, Chief Executive Officer & Director
June Lee Chief Operating & Development Officer
Taylor C. Harris Chief Financial Officer
Marc Semigran Chief Medical Officer
Michael P. Graziano Vice President-Research Biology
Sector and Competitors
1st jan.Capitalization (M$)
MYOKARDIA INC32.42%2 208
GILEAD SCIENCES7.84%100 614
VERTEX PHARMACEUTICALS20.45%45 997
REGENERON PHARMACEUTICALS-2.21%38 951
GENMAB5.93%10 457
NEUROCRINE BIOSCIENCES, INC.32.61%9 250